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Pancreatic cancer is highly chemoresistant. A major contributing factor is the characteristic
extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume.
Over the last decade there has been intensive research into the role of the pro-fibrogenic
pancreatic stellate cells (PSCs) and their interaction with pancreatic cancer cells. As a
result of the significant alterations in the tumor microenvironment following activation of
PSCs, tumor progression, and chemoresistance is enhanced. This review will discuss how
PSCs contribute to chemoresistance in pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is a highly aggressive malignancy with a notori-
ously dismal prognosis. Contributing to ∼227,000 annual deaths
worldwide, this insidious disease is the fourth leading cause of
cancer-related death in developed countries (Raimondi et al.,
2009; Hidalgo, 2010; Vincent et al., 2011). Remarkably, 80–85% of
patients present with unresectable and incurable tumors, putting
the median survival period at <6 months and the overall 5-years
survival rate at<5% (Hidalgo, 2010; Vincent et al., 2011).
A major contributor to this poor clinical outcome is pancre-
atic cancer’s prominent chemoresistance (Zalatnai and Molnar,
2007; Wang et al., 2011). In fact, the best treatments only prolong
life by ∼8–16 weeks (Wolfgang et al., 2013). Until recently, most
research efforts focused solely on cancer cells. However, signifi-
cant stakeholders in this chemoresistance are key pro-fibrogenic
cells of the pancreas known as pancreatic stellate cells (PSCs),
which when co-opted and activated by cancer cells, orchestrate
the strong desmoplasia that characterizes pancreatic cancer (Apte
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derived growth factor; TGFβ, transforming growth factor β; TNFα, tumor necrosis
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et al., 2004; Bachem et al., 2005). The resultant stromal land-
scaping yields an exclusive microenvironment where cross-talk
between cancer-associated human PSCs (CA-hPSCs) and cancer
cells promotes local tumor progression, metastasis and chemore-
sistance (Apte et al., 2004; Bachem et al., 2005; Hwang et al.,
2008; Vonlaufen et al., 2008a,b; Xu et al., 2010; Erkan et al., 2012;
Phillips, 2012).
CA-hPSCs establish fibrosis via excessive extracellular matrix
(ECM) deposition, which compresses and distorts intratumoural
vasculature, causing hypoxia (Olive et al., 2009; Phillips, 2012;
Stylianopoulos et al., 2012; Jacobetz et al., 2013). Hypoxia stimu-
lates the epithelial-mesenchymal transition (EMT) of cancer cells,
which is a more chemoresistant phenotype (Arumugam et al.,
2009; Kikuta et al., 2010; Wang et al., 2011). Furthermore, the
fibrosis sequesters chemotherapeutics in the stromal compart-
ment, impairing successful drug delivery to cancer cells (Olive
et al., 2009; Provenzano et al., 2012; Jacobetz et al., 2013). Despite
being in a hostile microenvironment replete with cytotoxic drugs
and hypoxia, CA-hPSCs not only survive, but actually thrive and
proliferate causing the tumor microenvironment to occupy up to
90% of the tumor volume (Li et al., 2010; Neesse et al., 2011;
Michl and Gress, 2013).
A major limitation to our understanding of the role of CA-
hPSCs in chemoresistance is their survival mechanisms in this
noxious microenvironment. However, mounting evidence sug-
gests CA-hPSCs are both direct and indirect drivers of pancreatic
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cancer chemoresistance and spread, and thus their inhibition may
potentiate current chemotherapy and intercept tumor-facilitatory
bidirectional interactions.
A GROWTH PERMISSIVE MICROENVIRONMENT
The histopathological hallmark of pancreatic cancer that under-
lies its aggressiveness is the severe desmoplastic and fibroin-
flammatory reaction which generates a high stromal-to-epithelial
ratio (Li et al., 2010). In fact, pancreatic ductal adenocarcinoma
(PDAC), which comprises >85% of all pancreatic cancer sub-
types, is one of the most stroma-rich malignancies (Bardeesy and
Depinho, 2002; Feig et al., 2012). Despite PDAC demonstrating
similar chemosensitivity as other cancers in vitro, PDAC patients
are less responsive to chemotherapeutics than other cancers (Li
et al., 2010), implicating the uniquemicroenvironment in PDAC’s
chemoresistance. Such desmoplasia facilitates a mechanopathol-
ogy known as growth-induced solid stress (GISS), resulting in col-
lapsed or compressed intratumoural blood vessels or lymphatics,
which respectively lead to increased hypoxia and interstitial fluid
pressure (IFP); both attenuate chemosensitivity (Stylianopoulos
et al., 2012). Non-invasive quantification of physiological param-
eters in human pancreatic tumors had confirmed that blood flow
is reduced and metabolic activity is increased relative to normal
pancreas (Komar et al., 2009). This recapitulates the significant
consequences of GISS, as deficient vasculature reduces blood flow,
yielding hypoxia (Stylianopoulos et al., 2012). Subsequently, stro-
mal and cancer cells undergo aerobic glycolysis—“The Warburg
Effect”—leading to their increased metabolic activity, as a means
of surviving in this hypoxic microenvironment (Tod et al., 2013).
The stroma in PDAC is composed of abundant ECM proteins,
such as collagen and hyaluronan, along with nerves, blood, and
lymphatics, and a versatile cellular population including inflam-
matory cells and activated PSCs (Erkan et al., 2010; Neesse et al.,
2011). Several paracrine and autocrine factors induce stroma
production (Li et al., 2010; Neesse et al., 2011; Phillips, 2012)
(Figure 1).
PANCREATIC STELLATE CELLS—KEY FIBROGENIC CELLS IN
PANCREATIC CANCER
In health, PSCs are quiescent, represent ∼4% of the cell pop-
ulation, express desmin, and glial fibrillary acidic protein and
store cytoplasmic vitamin A-containing lipid droplets (Apte et al.,
1998, 2006). The latter markers are PSC-specific, distinguishing
them from normal pancreatic fibroblasts. Disease onset her-
alds the accumulation of reactive oxygen species, cytokines and
growth factors secreted by injured cells, which can all activate
PSCs (Apte et al., 1999; Mews et al., 2002; Gao and Brigstock,
2005; Kordes et al., 2005; Vonlaufen et al., 2010) (Figure 1).
Such paracrine stimuli induce quiescent PSCs to
transdifferentiate into a myofibroblast-like phenotype, gain-
ing expression of α-smooth muscle actin (α-SMA) and losing
the anti-fibrogenic lipid droplets (Apte et al., 1998). These
morphological changes are accompanied by functional changes
(Figure 1), such as: (1) increased proliferation and migration
(Apte et al., 1999; Schneider et al., 2001; Mews et al., 2002;
Phillips et al., 2003b; Omary et al., 2007); (2) excessive synthesis
of ECM proteins as well as matrix metalloproteinases (MMPs)
and their inhibitors (Apte et al., 1999, 2004; Schneider et al.,
2001; Phillips et al., 2003a; Bachem et al., 2005); and (3) secretion
of growth factors and cytokines involved in autocrine loops that
perpetuate PSC activation (Shek et al., 2002; Ohnishi et al., 2003;
Aoki et al., 2006a,b; Omary et al., 2007; Jiang et al., 2009).
BIDIRECTIONAL INTERACTIONS BETWEEN PANCREATIC
STELLATE CELLS AND CANCER CELLS
Substantial evidence corroborates the notion that bidirectional
interplay occurs between cancer cells and CA-hPSCs, commen-
sally facilitating tumor progression (Apte et al., 2004; Bachem
et al., 2005; Hwang et al., 2008; Vonlaufen et al., 2008a; Xu et al.,
2010). Cancer cells recruit PSCs via mitogenic and fibrogenic
factors which promote PSC activation, proliferation, migration
and ECM remodeling capability. For instance, supernatants from
PDAC cell lines stimulated PSC proliferation and ECM synthe-
sis in a dose-dependent manner, with these effects abrogated
by neutralizing antibodies against platelet-derived growth fac-
tor (PDGF), fibroblast growth factor, and transforming growth
factor-β1 (TGF-β1) (Bachem et al., 2005). Also, PSC synthesis of
MMP-2, a protein crucial for basement membrane degradation,
is increased by ECM metalloproteinase inducer (EMMPRIN),
which is secreted by cancer cells (Schneiderhan et al., 2007). Such
modulation of the ECM is critical for degradation of basement
membrane and may influence cancer progression.
PSC recruitment is consequential for cancer cell behavior, as
stellate or cancer cell-derived growth factors, cytokines and ECM
components are sequestered in a fortified niche. For example,
Bachem et al. (2005) originally demonstrated that subcutaneous
co-injection of PSCs and cancer cells into nude mice acceler-
ated tumor growth relative to solely injecting cancer cells. This
was substantiated in an orthotopic mouse model which employed
intra-pancreatic co-injections of PSCs and cancer cells, replicat-
ing the aforementioned augmented tumor growth and showing
enhanced local and distant metastases relative to solely inject-
ing cancer cells (Vonlaufen et al., 2008a). Xu et al. (2010) also
demonstrated that CA-hPSCs co-migrate with metastasizing can-
cer cells, which is likely to aid cancer cell seeding and growth.
Furthermore, PSC-conditioned medium increased proliferation,
migration, invasion, and chemoresistance of cancer cells and
reduced their apoptosis in vitro (Hwang et al., 2008; Vonlaufen
et al., 2008a; Gao et al., 2010), while orthotopic co-injection
of PSCs and cancer cells increased primary tumor incidence
and size in vivo (Hwang et al., 2008). Moreover, co-culturing
with PSCs promoted EMT of PDAC cells (Kikuta et al., 2010).
Evidence by Watanabe et al. (2003) also demonstrated that exten-
sive intratumoural fibroblastic cell proliferation correlates with a
poorer disease outcome in pancreatic cancer patients. This signif-
icant evidence suggests that abolishing CA-hPSCs or their activity
may reduce PDAC’s aggressiveness, necessitating an improved
understanding of CA-hPSC survival mechanisms.
PANCREATIC STELLATE CELLS AND CHEMORESISTANCE OF
PANCREATIC CANCER
PDAC is highly refractory to chemotherapeutics (Wolfgang et al.,
2013). While the cause of chemoresistance is multifactorial,
three major processes have been distinguished: (1) reduced drug
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FIGURE 1 | Mechanisms of pancreatic stellate cell (PSC) activation. A
central feature of PSCs is the transformation from a quiescent (fat
storing phenotype) to an activated (myofibroblast-like phenotype) state.
Growth factors and pro-inflammatory cytokines released by neighboring
cells (pancreatic cancer cells, injured acinar or ductal cells, inflammatory
cells, and endothelial cells) all induce PSC activation. Activated PSCs
can then perpetuate this activation state via autocrine stimuli, leading to
increased proliferation, migration, and excessive ECM production. In
pancreatic cancer, activation of PSCs leads to the production of
extensive fibrosis which in turn contributes to disease progression,
metastases and chemoresistance. CTGF, connective tissue growth
factor; COX-2, cyclooxygenase-2; ECM, extracellular matrix; EMMPRIN,
extracellular matrix metalloproteinase inducer; ET-1, endothelin 1; IL,
interleukin; PDGF, platelet derived growth factor; TGF-β, transforming
growth factor β; TNFα, tumor necrosis factor α; TRAIL, TNF-related
apoptosis-inducing ligand.
uptake; (2) increased energy-dependent drug efflux; and (3) alter-
ations in cellular capabilities affecting drug cytotoxicity, such as
reduced apoptosis and dysregulated drug metabolism (Szakacs
et al., 2006; Zalatnai and Molnar, 2007). However, another major
determinant of pancreatic cancer chemoresistance is the extensive
fibrosis produced by PSCs, which results in significant intratu-
moural hypoxia and a self-perpetuating hypoxia-fibrosis cycle
(Figure 2) (Koong et al., 2000; Evans and Koch, 2003; Erkan
et al., 2009). CA-hPSCs extend this chemoresistant profile via
the hypoxia-fibrosis cycle (Masamune et al., 2008; Phillips, 2012).
This impairs drug delivery to cancer cells and stimulates their
EMT and genetic instability, yielding a more chemoresistant phe-
notype (Arumugam et al., 2009; Kikuta et al., 2010; Wang et al.,
2011).
Seminal proof-of-principle studies have substantiated the cru-
cial influence of the fibrotic hypovascular stroma on GISS and
chemoresistance in PDAC using genetically engineered mouse
models. One study interrupted hedgehog signaling in the stroma
(Olive et al., 2009), while two others enzymatically ablated
hyaluronan, the main ECM determinant of the fibrotic stroma
(Provenzano et al., 2012; Jacobetz et al., 2013). In all studies,
the stroma was dramatically depleted leading to increased intra-
tumoral vascular density and normalization of IFP. Following
stromal depletion, administering chemotherapeutics such as
gemcitabine or doxorubicin resulted in enhanced intratumoral
drug perfusion, rendering tumors vulnerable to cytotoxicity, and
hence inhibiting tumor growth and prolonging overall survival
(Olive et al., 2009; Provenzano et al., 2012; Jacobetz et al., 2013).
However, a Phase II clinical trial following the Olive et al. (2009)
study ceased due to increasedmortality in the treatment arm. This
may have resulted from removal of the tumor-containing fibrotic
barrier, encouraging the escape of aggressive clones which under-
went metastatic evolution in response to the microenvironment’s
high selection pressure, however this needs further investiga-
tion. Regardless, these landmark studies elegantly showed that
tumor-associated stromal collapse inmice is therapeutically effec-
tive. Hence, what if we deplete the stroma-producing CA-hPSCs
rather than the stroma itself? Since stromal and cancer cells have
been shown to contribute to GISS, their depletion can relieve it
(Stylianopoulos et al., 2012).
www.frontiersin.org April 2014 | Volume 5 | Article 141 | 3
McCarroll et al. Pancreatic stellate cells and chemoresistance
FIGURE 2 | Growth-induced solid stress (GISS), the hypoxia-fibrosis
cycle and their contribution to chemoresistance. Continuous PSC
activation results in excessive ECM deposition, particularly of
tensile-resistant fibrillar collagen as well as compression-resistant
hyaluronan. This eventually leads to prominent fibrosis which, along with
deformation caused by the number of proliferating stromal cells and cancer
cells, results in GISS. Consequently, this reduces the caliber of
intratumoral lymphatics and blood vessels. The former leads to increased
IFP, which can impair drug perfusion, while the latter reduces blood flow,
consequently leading to intrastromal and intratumoral hypoxia. This loops
back onto PSCs, driving their activation and hence generating more
fibrosis, which creates a hypoxia–fibrosis cycle. The cycle indirectly
contributes to chemoresistance by impairing drug delivery to cancer cells.
Moreover, hypoxia is capable of increasing the genetic instability and EMT
of pancreatic cancer cells, directly fuelling their chemoresistance. EMT,
epithelial-mesenchymal transition.
In addition to the hypoxia-induced chemoresistance, PSCs
can directly impact the response of cancer cells to chemother-
apy. hPSC secretions have been shown to confer a chemoresistant
cancer cell phenotype by (i) suppressing H2O2-induced apopto-
sis and increased survival of pancreatic cancer cells (Vonlaufen
et al., 2008a); and (ii) decreased pancreatic cancer cell sensitivity
to gemcitabine and radiation therapy (Hwang et al., 2008). These
results were supported by Muerkoster et al. (2004), who demon-
strated that pancreatic cancer cells co-cultured with PSCs are less
sensitive to etoposide. In addition, pancreatic cancer cells cul-
tured with ECM proteins produced by PSCs promoted resistance
to 5-fluorouracil (5-FU), cisplatin, and doxorubicin (Miyamoto
et al., 2004). However, a limitation in the field is that no studies
have examined the influence of PSCs on proteins which protect
tumor cells against chemotherapy agents (for example multi-drug
resistant drug transporters).
It is important to note that in addition to the impact which
stellate cells have on pancreatic cancer chemoresistance, it is now
well established that the immune cells also impact on tumor pro-
gression and chemoresistance (reviewed in Evans and Costello,
2012; Hamada et al., 2013). Immune cells within the tumor
microenvironment also activate PSCs (Figure 1), which may fur-
ther potentiate the effect of stellate cells on chemoresistance.
HYPOXIA AND CHEMORESISTANCE
Asmentioned above, hypoxia is a cancer driver that induces EMT,
a phenotypic change associated with increased chemoresistance
and invasiveness of cancer cells (Castellanos et al., 2013). In addi-
tion, hypoxia increases genomic instability by elevating intracel-
lular levels of mutagenic reactive oxygen species and suppressing
DNA repair (Bristow and Hill, 2008; Chan and Bristow, 2010).
This microenvironment selects for cancer cell clones carrying
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mutations and phenotypic alterations that improve their sur-
vival, increase chemoresistance, and enhance migration out of
the inhospitable microenvironment to metastatic sites (Bao et al.,
2012).
The cellular effects of hypoxia are primarily initiated by
hypoxia-induced factor-1 alpha (HIF-1α), a well-established
marker for cells under hypoxic stress (Ke and Costa, 2006). HIF-
1α contains an oxygen-responsive degradation domain that is
hydroxylated under normoxic conditions by prolyl hydroxylases,
leading to ubiquitination and rapid proteasomal degradation
(Srinivas et al., 1999; Masson et al., 2001). Low oxygen levels inac-
tivate these prolyl hydroxylases, stabilizing HIF-1α, allowing it
to heterodimerize with HIF-1β, forming HIF-1, a transcription
factor that regulates numerous genes responsible for the cellular
response to hypoxia (Greijer et al., 2005; Semenza et al., 2006).
HIF-1α has been detected in both pancreatic cancer cells and
surrounding stromal cells, in pancreatic cancer tissue specimens
(Shibaji et al., 2003; Ide et al., 2007; Sun et al., 2007; Hoffmann
et al., 2008; Schwartz et al., 2010). Positive staining correlated with
increased lymph node metastases, decreased apoptotic index,
increased intratumoral microvessel density, advanced tumor stage
and poorer overall survival (Shibaji et al., 2003; Ide et al., 2007;
Sun et al., 2007; Hoffmann et al., 2008; Schwartz et al., 2010).
The influence of hypoxia on pancreatic cancer growth and
metastatic spread has been more directly investigated in mouse
models of the disease. Buchler et al. (2004) used an ortho-
topic mouse model of pancreatic cancer that develops distant
metastases and measured primary tumor oxygenation using the
Eppendorf histograph. The group found a significant correla-
tion between lower tumor oxygenation and increased metastatic
score (Buchler et al., 2004). Chang et al. (2011) later reiterated
these results using orthotopic implants of pancreatectomy sam-
ples from pancreatic cancer patients. The group measured intra-
tumoral hypoxia by immunohistochemistry using the hypoxia
marker EF5, and observed a correlation of higher EF5 staining
with rapid tumor growth, increased proliferation and increased
metastases (Chang et al., 2011). Ide et al. (2007) suggested a
potential molecular pathway for the increased invasiveness by
associating increased levels of HIF1α with elevated paracrine
signaling proteins hepatocyte growth factor and c-met in pancre-
atic cancer tissue specimens. Importantly, Salnikov et al. (2009)
showed that while hypoxia drives EMT in both cancer stem cells
and cancer cells, it is the stem cells that gain the more invasive
phenotype.
Hypoxia in pancreatic cancer also selects for cancer cell clones
with phenotypic changes that confer a survival advantage and
consequently enhance their aggressiveness and chemoresistance.
Erkan et al. (2005) nicely demonstrated this influence in their
investigation of BNIP3, a hypoxia-inducible pro-apoptotic gene,
in pancreatic cancer cells and pancreatic cancer patient sam-
ples. They firstly observed that downregulation of BNIP3 in
patient samples correlated with poorer patient survival. Upon
silencing BNIP3 in pancreatic cancer lines in vitro, the group
observed a marked increase in chemoresistance to 5-FU and
gemcitabine (Erkan et al., 2005). The results suggested that the
hypoxic microenvironment imposes selective pressure that favors
PC cells with the ability to bypass cell death mechanisms, and
as a consequence, that can better resist chemotherapeutics. In
addition, Arumugam et al. (2009) have demonstrated the link
between hypoxia-induced EMT in pancreatic cancer cells and
resistance to 5-FU, gemcitabine and cisplatin in vitro. Tumor cells
under hypoxia are also driven to switch their metabolism from an
oxygen-consuming pathway to a glycolytic pathway of ATP pro-
duction (Chen et al., 2009). Such an environment selects for cells
with enhanced glycolytic activity, as evidenced by increased levels
of glycolytic enzymes in pancreatic cancer tissues and the corre-
lation of glycolytic enzyme polymorphisms with poorer overall
survival and enhanced tumor growth (Mikuriya et al., 2007; Dong
et al., 2011).
PSCs are also influenced by hypoxia, leading to phenotypic
changes that further stimulate pancreatic cancer cells and that
facilitate the self-perpetuation of hypoxia. Masamune et al. (2008)
investigated the effect of hypoxia on human CA-PSCs in vitro.
When cultured under hypoxic conditions, CA-PSCs exhibited
increasedmigration and type I collagen production, allowing per-
petuation of fibrosis and hypoxia. Conditioned media from these
cells also induced endothelial cell proliferation, migration and
angiogenesis via increased PSC-mediated VEGF production, both
in vitro and in vivo (Masamune et al., 2008). Spivak-Kroizman
et al. (2013) showed that hypoxia also indirectly induces collagen
secretion in PSCs, by increasing PC cell sonic hedgehog secretion.
Erkan et al. (2009) reconciled the apparent contradictory role of
PSCs in perpetuating hypoxia via induction of fibrosis, and in
reducing it via pro-angiogenic signals. Using co-culture of PSCs
and PC cells in vitro, the group showed that although hypoxia
alone drives a proangiogenic PSC phenotype, activated PSCs
induce PC cells to increase anti-angiogenic endostatin produc-
tion, thus perpetuating hypoxia by inhibiting angiogenesis. More
recently, Eguchi et al. (2013) demonstrated that hypoxia indi-
rectly increases the invasiveness of PC cells in vitro, by inducing
secretion of connective tissue growth factor from PSCs. It is there-
fore not surprising that many anti-angiogenic therapies result in
increased metastases, as they create a hypoxic microenvironment
that favors this phenotype (Ebos et al., 2009; Paez-Ribes et al.,
2009). The major role of PSCs in establishing and perpetuating
the hypoxic microenvironment makes them ideal therapeutic tar-
gets in pancreatic cancer. Given PSCs regulate ECM turnover,
such an approach would ideally include co-administration of
an anti-fibrotic reagent such as pirfenidone, to ensure fibrolysis
occurs after targeting PSCs.
POTENTIAL STROMAL TARGETING AGENTS IN THE CLINIC
One reason drug trials have failed in pancreatic cancer is due
to inclusion of all patients in a particular trial, regardless of the
biological characteristics of an individual’s tumor and no con-
sideration of the stroma, which based on the evidence provided
above is likely to influence a patient’s response to chemotherapy.
Understanding how stromal proteins influence drug resistance,
drug delivery and patient survival has the potential to help clin-
icians make better use of available treatments to improve the
outcome of patients with pancreatic cancer. Importantly, pro-
tein expression profiles of the stroma are now considered strong
predictors of patient outcome (Conklin and Keely, 2012). For
example, high stromal activity (αSMA positive PSCs) correlates
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with poor prognosis in pancreatic cancer patients (Erkan et al.,
2008). Below we include discussion on a few of the promising
stromal targeting therapies currently being investigated in the
clinic.
At the 2013 ASCO meeting, a phase 1b study of gemcitabine
plus PEGPH20 (PEGylated recombinant human hyularonidase)
in patients with stage IV previously untreated pancreatic cancer
was presented by Hingorani et al. (2013). PEGPH20 works by
enzymatically depleting hyaluronic acid (a glycosaminoglycan),
which is extremely abundant in pancreatic cancers and thought
to contribute to the high interstitial fluid pressure (Thompson
et al., 2010). The study separated out the nine patients with high
levels of stromal hyaluronan and five of these patients showed a
partial response to PEGPH20 treatment (response rate 56%). In
addition, the PEGPH20 appeared to be well tolerated. The scien-
tific and clinical community eagerly await the results of Phase II
studies.
A Phase 3 trial is currently testing gemcitabine in combina-
tion with TH-302 in patients with locally advanced unresectable
or metastatic pancreatic adenocarcinoma. As outlined above,
pancreatic cancer is highly hypoxic and TH-302 is a chemother-
apeutic agent which is selectively activated in a hypoxic tumor
microenvironment (Sun et al., 2012).
Angiotensin II type I receptor inhibitors have also been
explored as potential therapeutics to inhibit PSC activity. For
example, Yamada et al. (2003) demonstrated that oral adminis-
tration of candesartan (a widely used angiotensin II type-I recep-
tor inhibitor) decreased ECM production and αSMA expression
(activated PSC marker) in a rat chronic pancreatitis model.
Furthermore, a retrospective clinical study suggested that pan-
creatic cancer patients treated with angiotensin II type 1 receptor
inhibitors in combination with gemcitabine may have improved
clinical outcome (Nakai et al., 2010). To expand on these findings
the same authors recently completed a multicenter phase II clini-
cal trial (35 patients with advanced pancreatic cancer) to examine
whether patients treated with candesartan in combination with
gemcitabine would have improved survival. The treatment regime
was tolerated using moderate doses of candesartan with gemc-
itabine, but failed to demonstrate any significant clinical activity
(Nakai et al., 2013).
More recently, in an elegant and comprehensive study by
Chauhan et al. (2013), the angiotensin II Type 1 receptor inhibitor
losartan was found to reduce stromal collagen and hyaluronan
production, as well as decrease the number of αSMA positive
PSCs in orthotopic pancreatic tumors. As a result, the treatment
of tumors with losartan reduced GISS and increased vascular per-
fusion. The overall outcome was reduced hypoxia and increased
sensitivity to chemotherapy agents. This promising pre-clinical
study has now moved forward to a clinical trial in pancreatic can-
cer (NCT01821729). Notably, losartan has been shown to have a
higher tumor penetration when compared to other angiotensin II
Type 1 receptor inhibitors including candesartan. Indeed, inad-
equate tumor penetration of candesartan may in part explain
its modest effect on chemosensitivity in the recent clinical trial
(Nakai et al., 2013).
A recent article by Kozono et al. (2013), demonstrated
that an anti-fibrotic agent pirfenidone decreased tumor
growth/metastases and increased drug sensitivity in a mouse
orthotopic model of pancreatic cancer (co-injection of PSCs and
tumor cells into the pancreas). Pirfenidone is currently approved
for the treatment of idiopathic pulmonary fibrosis in Europe and
based on evidence by Kozono et al. (2013), it may be a promising
anti-fibrotic agent which can be repurposed to reduce the activity
of PSCs in pancreatic cancer.
Finally, Nab-paclitaxel or Abraxane® (Abraxis Bioscience)
has generated great interest as a novel therapeutic for pancre-
atic cancer. A recent phase III MPACT (Metastatic Pancreatic
Adenocarcinoma Clinical Trial) trial demonstrated that the addi-
tion of Nab-paclitaxel with gemcitabine was able to significantly
improve the median survival of metastatic pancreatic cancer
patients (8.5 months) when compared to gemcitabine treated
only arm (6.7 months) and reduce toxicities (neuropathy and
neutropenia) commonly associated with the cremaphor for-
mulation used to dissolve paclitaxel thereby, allowing for a
higher paclitaxel dose to be delivered to the patient (Von Hoff
et al., 2013). Interestingly, several studies have also shown
that Nab-paclitaxel alone or in combination with gemcitabine
depletes PCSs and desmoplastic stroma (Von Hoff et al.,
2011; Alvarez et al., 2013). Moreover, it is hypothesized that
the albumin-bound Nab-paclitaxel may selectively accumulate
in the pancreatic stroma via its binding to secreted protein
acidic and rich in cysteine (SPARC) matricellular glycoprotein
which binds albumin and is overexpressed in tumor stroma.
Indeed, high SPARC expression has been correlated to poor sur-
vival outcome and has been suggested as a possible predictive
biomarker for Nab-paclitaxel (Von Hoff et al., 2011; Alvarez
et al., 2013). However, a recent study by Neesse et al. (2013)
showed that the effects of Nab-paclitaxel were largely dose-
dependent and that SPARC expression in the tumor stroma
did not influence drug accumulation in a pancreatic cancer
mouse model. However, they did report increased Nab-paclitaxel
concentrations in plasma suggesting a potential interaction with
circulating SPARC. Therefore, it is possible that high circu-
lating SPARC may aid in increased drug retention and tis-
sue delivery. Future studies will be needed to evaluate tissue
and plasma SPARC expression as a predictive biomarker for
Nab-paclitaxel.
FIGURE 3 | The potential therapeutic implication of targeting both
pancreatic cancer cells and pancreatic stellate cells in pancreatic
cancer.
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CONCLUSIONS
As outlined above, a significant body of work corroborates the
notion that CA-hPSCs are not relegated to a bystander role in
PDAC chemoresistance, but instead, they are critical in driv-
ing it via both direct and indirect mechanisms. This occurs by
way of PSC generated fibrosis creating a hypoxic microenvi-
ronment that directly fuels the chemoresistance of cancer cells.
Concurrently, fibrosis impairs effective drug perfusion to cancer
cells, which indirectly augments chemoresistance. Furthermore,
there is mounting evidence that not only is stromal depletion
therapeutically possible in mice with pancreatic tumors, but it
also facilitates the delivery of chemotherapeutics to pancreatic
tumors. Notably, stromal depletion entails a reversion of fibro-
sis as well as a decline in the number of cells generating fibrosis
because reducing the number of activated PSCs in turn would
diminish collagen production. Thus, in light of their major con-
tribution to fibrosis in pancreatic cancer as well as their highly
proliferative capacity, cancer-associated PSCs are ideal candidates
for the identification of stromal-related therapeutic targets that
may act as additional targets for potentiating existing chemother-
apeutics (Figure 3).
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